Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Posttransfusion purpura is an increasingly rare complication of blood transfusion. It is characterized by an acute episode of severe thrombocytopenia occurring about a week after a transfusion in HPA-1a negative women who have been alloimmunized by pregnancy. Although the thrombocytopenia resolves spontaneously within a few weeks, haemorrhage is common and sometimes severe. High-dose intravenous immunoglobulin (IVIgG) (2 g/kg given over 2 or 5 days) is the current treatment of choice to shorten the duration of thrombocytopenia, with responses in about 85% of cases. The pathophysiology remains uncertain. Universal leucocyte reduction of blood components in the UK has resulted in a marked reduction in the number of reported cases. This edition first published 2013 © 2001, 2005, 2009, 2013 John Wiley & Sons Ltd.

Original publication





Book title

Practical Transfusion Medicine

Publication Date



127 - 131